Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic SyndromeStrengthened the Board of Directors and Management Team with Multiple Appointments REDWOOD CITY, Calif., Aug....

Related Keywords

United States ,Edwinj Tucker ,Patricia Carlos ,Stephenj Galli ,Ronald Martell ,Daniel Adelman ,John Mullaly ,Scott Brun ,Lauren Barbiero ,Annette Marcantonio ,Jasper Therapeutics Inc ,Moffitt Cancer Center ,Nasdaq ,Management Team ,Development Rd Expenses ,Equality Affairs ,First Patient Dosed ,Lower Risk Myelodysplastic ,Chief Executive Officer ,Scientific Advisory ,Chief Medical ,Senior Vice President ,Vice President ,Cash Equivalents ,Chronic Spontaneous Urticaria ,Intermediate Risk ,Annual Report ,Months Ended June ,Stockholder Equity ,